Center for Drug Evaluation
and Research (CDER)
ANTIVIRAL DRUGS ADVISORY COMMITTEE (AVAC) MEETING
Clinical Trial Design Issues in the Development of Topical Microbicides
for the Reduction of HIV Transmission
Holiday Inn -
PRESENTATION TO THE
OPEN PUBLIC HEARING
on behalf of the
Ad Hoc Subcommittee of the
(submitted a priori as
written public comment)
TEL
301-588-8091; FAX –8390; pharrison@microbicide.org
www.microbicide.org
Introduction
This presentation addresses core issues in microbicide clinical trial
design that have been under consideration by an Ad Hoc Subcommittee of the Alliance for Microbicide Development
since the Alliance “Mini-Summit on Clinical Trials” held in March in
Washington, DC (see Appendix A for
Subcommittee roster). The Subcommittee does not presume to speak for “the
microbicide field” as some sort of organized whole, but finds that it
represents substantial consensus across that field. Some of that consensus will
be reiterated in other individual formal presentations and written comments
provided to the Antiviral Drugs Advisory Committee, as will, of course, any
significant divergence of opinion.
We wish to note that the discussions that led to the writing and
subsequent review of this document were completed before the FDA’s Briefing Information document was posted
on the agency’s web site. However, the two documents do correspond in their
overall focus and emphases on the major components of microbicide clinical
trial design.
The Fundamental Issue: The Need for Microbicides
A Large Global
Population at Particular Risk. The increasing intensity of focus on topical
microbicides emerged largely from the recognition that HIV/AIDS increasingly
has a “woman’s face”[1].
Worldwide, almost half of the 37.2 million adults living with HIV/AIDS at
end-2002 were female and, of the 5 million new infections in that year, 40%
were in women. Those percentages are even higher in sub-Saharan
Yet
research indicates that many women in many geographic and sociocultural
settings are reluctant or unable to talk with their partners about use of
condoms, the one existing preventive technology offering reasonable protection
against sexually transmitted infections (STIs). This is true in both developed-
and developing-country settings, and notably true for women disadvantaged by
economic dependence, poverty, and gender discrimination who cannot risk their
relationships by questioning partner fidelity.[6]
Consistent condom use has been found
universally hard to achieve in stable relationships, and there are few examples
over 20%; even individuals willing to use condoms with “outside” partners
appear unwilling or unable to use them with a primary, stable partner. Further,
in cultures where childbearing is linked to self-worth and societal position,
the prospect of childlessness often outweighs considerations of risk.[7]
The Potential
Value of Microbicides. Microbicides, as an
innovative preventive technology whose use need not depend on partner
cooperation or even knowledge, would offer women for the first time the ability
to determine their own protection. A major modeling exercise by the London
School of Tropical Medicine and Hygiene found that a 60% efficacious microbicide used by 20% of women in 73 lower-income
countries (including all of sub-Saharan Africa) in 50% of sex acts where
condoms were not used would avert 2.5 million HIV infections over three years
in women, men, and children, saving $2.7 billion in health care costs and $1
billion in lost productivity.[8] These
savings estimates are probably modest: according to the recently-issued UNDP Human Development Report, 54 countries
are now poorer, 21 countries have worse hunger problems, and 34 have
experienced declines in life expectancy since 1990, primarily because of
HIV/AIDS.[9]
The
potential of microbicides as a new preventive technology is further promoted by
the fact that the search for an HIV vaccine, which would theoretically protect
both males and females, is proving far more complex than anticipated, and
remains a distant possibility.[10]
This means that microbicides could be, at a minimum, a critical preventive
technology for what may be a long interim period until an HIV vaccine
materializes. Even after that, since microbicides and vaccines will each
provide only partial protection, a strong argument can be made for them both as
complementary preventive technologies, particularly in the case of microbicides
offering a broader spectrum of protection against different HIV clades and any
non-HIV STIs or vaginal infections acting as co-factors for HIV transmission.[11]
It may well be, in fact, that microbicides and/or vaccines that could elicit
durable mucosal immunity, thus targeting the earliest stages of HIV infection,
might offer the best prospects for preventing or containing HIV infection.[12]
Background Issues
The
Subcommittee recognizes and honors the FDA’s mandate to protect the health and
safety of the
First,
such products typically fail to attract the involvement of “Big Pharma”, so
that their development becomes a patchwork effort across the public, nonprofit,
and biotechnology sectors which can generate inefficiencies that may confound,
or be especially confounded by, regulatory processes.
Second,
the bulk of clinical testing of these products must by definition take place
outside the
Third,
FDA approval may be construed as the “gold standard” by regulatory authorities
outside the
Cutting
across these factors are two others: (1) the urgency imposed on all areas of
relevant research by the rapid escalation and expansion of the HIV/AIDS
pandemic, and (2) the divergence between epidemiological risk-benefit ratios in
countries of origin and those in countries of use.[18]
The need for urgency should be obvious and has been acknowledged operationally
by the FDA, whose pace of approval of new HIV therapeutics has accelerated
dramatically; however, whether the mechanisms used to speed development of HIV
therapeutics might fit the case of microbicides is unclear.[19] As a product category intended for continued
use over time by “healthy” people for disease prevention, microbicides, like
HIV vaccines, raise challenges for testing unlike the testing of products
intended for those who are already ill.
What
is also unclear yet utterly central is how regulatory processes can take into
account the differences between the enormous volume of risk in the countries
which, in the case of HIV/AIDS, bear roughly 95% of the burden of disease and
corresponding risk, and the volume of risk in countries where the burden of the
epidemic is considerably less.[20]
The question here, for the FDA and the microbicide field, is how to act
expeditiously while striking an appropriate balance among consummate scientific
rigor, ethical treatment of human subjects, and what is realistically feasible
and truly informative.
Need for a Paradigm Shift
If
we accept the foregoing issues as valid, then it becomes evident that some sort
of “paradigm shift” is needed in the testing and approval of certain product
categories for certain populations. Indeed, the dimensions of such a shift with
respect to HIV vaccines are already under active consideration by the World
Health Organization and the EMEA (European Agency for the Evaluation of
Medicinal Products) in a process that includes representation from the FDA’s
Center for Biologics.[21]
The position of the FDA to
date with respect to microbicides has been to maintain flexibility and consider
the new products in this new field on a case-by-case basis. We vigorously urge
continuance of this position. The very fact of an evolving technology, the
intrinsic differences between traditional therapeutic trials and trials of
preventive technologies, continued limits on understanding of the correlates of
protective immunity in HIV infection,[22]
lack of validated surrogates for product efficacy, and the dominance of needs
for offshore testing together recommend a regulatory posture that is
persistently flexible. We applaud the agency in its search for clarity and its
ongoing and present efforts to involve the wider community of microbicide
research and advocacy in that search. At the same time, we respectfully submit
that a regulatory strategy for Phase II/III studies that is unduly complex,
demanding, and rigid may not be feasible in developing-country settings and
could, in fact, compromise safety, data quality, ethical integrity, and
research specificity. We argue for simpler studies that successively substitute
data from multiple sources for what are presently assumptions, address only the
major issues for worldwide regulatory approval, provide a sound basis for Phase IV and/or post-market monitoring, and are doable at a
reasonable level of confidence. Finally, we urge the leadership of the FDA and
CDER to become active participants in the advancing dialogue on the particular
challenges of developing pharmaceutical products for developing-country
populations.
In
the spirit of this argument, we offer the following observations, presented
according to what we agree to be the strengths and limitations of each major
element in the design of clinical trials to evaluate product effectiveness. We
agree that trials must be large enough to ensure sufficient HIV end-points to
provide a robust, statistically significant result; that enrollment must occur
at various sites where there is a high incidence of new HIV infections; that
bridging studies in US populations will in some cases make sense; and that the
recruited populations should share the main characteristics of the eventual
target groups for Phase 3 and beyond. Thus, we will focus only on the main
components of trial design, which will, of course, be affected by HIV incidence
and will, in turn, affect and be affected by trial sample size. These
components are (1) control arms, (2) trial duration/duration of follow-up, (3)
strength of evidence and level of effectiveness, and (4) adherence and its
measurement.[23]
Control Arms
Randomized
controlled trials of new drugs are classically blinded and commonly include
randomization of participants to either drug or inactive product (placebo) to
control for observer bias and differential behavior. In the case of
microbicides, a completely inactive or “inert” placebo remains to be identified.
For example, a placebo might contain antimicrobial components in the form of
preservatives or charged jelling agents, have an acidic pH disfavoring
infection, provide lubrication reducing physical trauma to the mucosa, or act
as a physical barrier to infection by coating the mucosa, thus producing some
kind of protective effect in itself. Considerable work has been done to develop
a placebo that would minimize the potential for protective effect, as reported
in regulatory submissions in preparation for HPTN 035. Alternatively, a placebo
might have some harmful effect, though this is speculative and believed highly
unlikely for the hydroxyethyl and methyl cellulose gels that have been
specially developed for trial use as part of ongoing efforts to minimize any
possible protective effect. Some trial designers propose that this “placebo
problem” can be circumvented by using a condom-only (no-treatment/no-product)
arm so that the HIV rate in the microbicide arm may be compared directly with
the baseline rate in that population.
The
question here is whether a condom only/no-product arm is essential in
effectiveness trials of topical microbicides. Further questions would have to
do with the circumstances under which such a control arm could be dropped in
the course of a given trial and whether such a control would be necessary for
every tested product.
STRENGTHS. Comparison of placebo (P)
and condom-only (C) can provide a valid estimate of the effects of a placebo,
assuming that behavior (i.e., condom use and other risk-taking behavior)
remains independent of group assignment. Comparison of active treatment (T) and
condom-only (C) can provide an estimate of the combined effect of microbicide
use plus behavioral changes due to availability of microbicides, i.e., an
estimate of “real world” or “use-effectiveness”.
LIMITATIONS. By definition, a condom-only
arm cannot be blinded. This means that differences in HIV rates, in whichever
direction (protection or potentiation), may be due as much to different risk
behaviors as to the direct biological effect of the product, even though
participants are told that the effectiveness of the microbicide is unknown.
Some have argued that it is not necessary to understand the basis of any
observed difference in HIV rates between arms as long as the situation reflects
“real life”. But a comparative study of treatment against condom-only does not
reflect real life: when the microbicide comes to market, there will be no
informed consent procedure, no regular safer sex counseling, and no clinical
trial ethos to influence user risk behavior. The arguments laid down under
“Strengths” above can be seen as essentially contradictory and requiring of
contradictory assumptions. Comparing P to C requires the assumption that the
associated behaviors do not differ, whereas in comparing T to C
(“use-effectiveness”), we are allowing for the fact that behaviors might, in
fact, differ.
It
is also not certain that enough women can be motivated to possible
randomization to a condom-only arm and comply with the protocol for the full
length of the trial, including regular clinic visits for blood tests, etc.,
since the inducement of receiving product/placebo would not pertain. The
differential in inducement raises an ancillary question: those who advocate for
inclusion of a condom-only control have alluded to use of self-reported data to
compare risk-taking behaviors across groups although, as observed later in this
document (see section on Adherence),
our methods for assessing such behaviors remain limited. An unblinded control
arm for which a core incentive to participants (i.e., access to test product)
is lacking imposes further complexity on behavioral assessment that is now—and
may remain—imponderable. Finally, the possibility of heavy losses to follow-up
in a no-product arm could introduce significant bias if, for example, dropouts
tended to be those who found condom use difficult or thought themselves more or
less likely to have been infected.
RECOMMENDATION: The Subcommittee believes that the additional data a condom-only arm
might furnish are likely to include more noise than useful information, may be
uninterpretable, and could lead to erroneous conclusions about the products
being evaluated. While there is no intent to imply that cost savings should
take precedence over good science, we contend that cost savings resulting from
the elimination of a condom-only arm might be better invested in increasing the
power of the product and placebo arms and, possibly, Phase IV studies as more
accurately reflective of “real-world” effectiveness. Still, we understand that
there is considerable commitment to including a condom-only/no-treatment arm in
the forthcoming HPTN 035 trial of PRO2000/5 and BufferGel. We recognize that
the findings from the HPTN 035 trial could influence future regulatory policy,
but argue that until those findings become available, which could be several
years away, it would be unwise to lock in a regulatory requirement for a
no-treatment arm. Given the implications of such an arm for sample size,
recruitment, follow-up, costs in time and resources, and questions about
generalizability to other candidate products, we therefore urge a highly
flexible position with respect to inclusion of a condom-only arm in future
effectiveness trials.
Trial Duration/Duration of Follow-up
The
question here is: how long should participants be followed in Phase II and III
trials of microbicides? Our understanding is that the FDA is looking for
periods of on-treatment evaluation of 12-24 months, with all participants
treated until the last recruit enrolled has completed 12-24 months of
treatment. We do not know FDA’s thoughts about duration of off-treatment
follow-up.
STRENGTHS. Longer duration of
follow-up permits accumulation of more person/years of safety data and efficacy
endpoints in conjunction with chronic use of product over time. This
theoretically permits smaller sample sizes, in itself a benefit in terms of
costs and logistics. Longer studies would also be advantageous if rates of
sero-conversion were uneven over time, since such variability would be more
likely to be captured; however, field experience to date has found that such
rates are steady, so that there would seem to be no particular advantage to a
longer period of follow-up if this is a desired objective.
LIMITATIONS. With longer periods of
follow-up, adherence may decrease with respect to both product use and clinic
attendance, for a variety of reasons, including real and perceived side
effects, withdrawals for pregnancy, and simply participant fatigue. Large loss
to follow-up compromises study power almost by definition, can erode data
quality as well as quantity, and may have an overall negative effect on study
reliability and consequent regulatory assessment. Large losses to follow-up can
also lead to bias if the reasons for the losses differ between study arms; they
might also lead to an amount of variability across multiple trial sites that
could be confounding.
RECOMMENDATION:
The Subcommittee appreciates the desire of
the FDA to capture as much data on putative product toxicity as possible. There
is, nevertheless, no “magic time” that could unimpeachably predict toxicity,
particularly against the background of extremely high risk that characterizes
HIV-pandemic countries. Consideration is being given to trial designs in which
the required woman-years of participation are achieved by enrolling a
substantially larger number of women (perhaps requiring more trial sites) who
are followed for a shorter time, e.g., 6 months. The logistical and cost
implications of a strategy requiring a large overall number of recruits to get
the same reliability would be partially offset by the larger numbers needed for
studies with longer follow-up which need to compensate by “over-recruiting” to
account for drop-outs and withdrawals. Expectations from this temporal
compression are that losses to follow-up and any consequent biases would be
significantly smaller. Longer-term safety and acceptability data would be
derived from sites where longer follow-up of good quality proved feasible.
We believe that such
approaches offer a defensible balance between the ideal and the practicable,
and propose a period of on-treatment evaluation of no more than 12 months per
participant. We note that the potential for advance understandings about
post-licensure surveillance studies has not been adequately explored and urge
such exploration. Finally, we suggest scrutiny of the strategies employed in
studies of contraceptive safety and effectiveness as a possibly informative
analogue.
Strength of Evidence and Level of Effectiveness
The
question here is: What minimum level of effectiveness should a Phase III
microbicide trial aim to demonstrate, and with what degree of confidence? (We
note parenthetically that in pursuing answers to that question, it is important
to define what we are talking about. A Phase III microbicide trial does not
measure the product’s efficacy, i.e.,
its innate anti-infective potency, but rather its effectiveness in reducing the infection rate when used as it was in that particular trial. It
may be that more consistent use in “real life” subsequent to the trial might
well result in even fewer infections.)
Results
from two adequate and well-controlled Phase III trials, each independently
convincing (p: 0.05 x 0.05 = 0.0025),
are generally required by the FDA to establish product effectiveness for
licensing approval. Nonetheless, FDA has indicated that it would consider
approving a microbicide on the basis of a single, large, multi-center, well-designed,
and well-executed Phase III trial.[24]
For such a trial, a one-sided p value
of 0.000625 (0.025 x 0.025, 0.001 two-sided) has been mooted, with the
objective of showing significance at the same level as from two independent
studies. There are, however, indications that the FDA might consider a value
between 0.001 and 0.01, assuming that key criteria for study quality were met.
STRENGTHS: Obviously, the p
value articulated above offers greater likelihood of licensure based on the
results of a single trial. As for level of microbicide effectiveness, most
product developers would regard an effectiveness level of about 33% (one-third
fewer infections in the microbicide arm than in the control arm) as the minimum
acceptable, in the belief that anything lower would be of dubious practical
value. Furthermore, the number of women required, and hence the trial’s
practicability and costs, would increase dramatically to detect a lower
effectiveness with the same degree of confidence. In any event, if a trial designed
to detect 33% effectiveness were to actually show greater protection, say
50-60%, confidence in the result would be correspondingly greater.
LIMITATIONS: We offer just one example of
the potential implications of the p value
stipulated above, in association with a 33% effectiveness level. In a
population with 2% annual HIV incidence, a two-arm trial with 2 years of
follow-up and 90% power to detect 33% effectiveness at this significance level
would require approximately 28,000 woman-years of data, or 7,000 women in each
arm ─ a challenging target with heavy budgetary implications if we accept
prevailing estimates of a per-volunteer cost of from US$3,500 to $5,000.
Arguments that have been made against attempting such a trial have been
predicated on feasibility, in turn predicated on implications for site number
and capacity, recruitment potential, and costs.
RECOMMENDATIONS:
The
consensus of the Subcommittee is that we are in what is essentially a data-free
zone with respect to decisions about the intertwined variables of level of
effectiveness, strength of evidence, trial duration, and number of control
arms. We respectfully ask the Advisory Committee to examine the table of
alternative design scenarios prepared by the HPTN 035 protocol team, which is
provided as an Appendix to this
document, and to scrutinize its various implications. The table is based on a
33% effectiveness target, but consideration is being given by some product
sponsors to a 50% effectiveness level. Since the 33% level is presently
theoretical and there is as yet no basis for arguing too hard one way or the
other, we submit that this is another area
where regulatory flexibility would be appropriate. We observe that elimination
of the condom-only/no-treatment arm and shortening the period of follow-up
(even accounting for the concomitant sample size increases mentioned earlier)
could produce savings in time and costs that need not compromise the essential
quality of microbicide effectiveness trials, particularly given the acute public
health need which motivates them. As the closest example, the HPTN 035 trial,
we vigorously urge that the AVAC question what is to be defined as a “win”[25]
for the microbicides being tested. Is it essential that the product in question
“beat” both a placebo and a no-treatment/condom-only arm, or might a victory
over the former (perhaps with the other going in “the right direction”,
assuming interpretability), be sufficient, and how might “beating” and
“sufficient” be defined?
Adherence
Admittedly
limited experience in the trials of COL-1492 informs us that within a
multi-site microbicide trial, as noted above, any observed differences in
effectiveness among sites may be due, at least in part, to different adherence
levels.
STRENGTHS. Trustworthy information about adherence
during a trial is relevant both to interpreting results and formulating claims
about the product’s protectiveness, and high confirmed levels of product use
during Phase III will be critical to obtaining product registration. We believe
that it is useful for regulators to be aware that behavioral research and trial
experience have accumulated and advanced over the last few years in quantity
and quality. It is reasonable to expect improvement in existing approaches
(e.g., coital logs, diaries, questionnaires, and in-depth interviews) and/or
their replacement with more rewarding techniques that could inspire greater
confidence in trial results.
LIMITATIONS. Nonetheless, there is yet
no “true” measure of product adherence, since in microbicide trials it is
understandably difficult to obtain invariably reliable feedback from
participants on sexual behavior and microbicide and condom use.
RECOMMENDATION:
This is not a recommendation to the Advisory
Committee but, rather, an acknowledgment for its information. Despite deepening
understanding about what behavioral research can produce in the way of
microbicide trial quality and reliability, the Subcommittee agreed that the
field has work to do with respect to learning from other drug trials about
protocol adherence, and that efforts dedicated to promoting adherence to
product use are as important and urgent as research aimed at developing
microbicides with greater potency.
HPTN 035
Design Scenarios, 33% Targeted Effectiveness
Option |
Active
Product Arms |
Control
Arms |
Power |
Final
2-sided p value |
Non-US Person-Years* |
Non-US
Sample Size** |
Yrs |
No.
of Mos. |
Total
Costs |
1a |
1 |
1 |
80% |
0.05 |
4810 |
2749 |
1.75 |
21 |
23,088,000 |
1b |
1 |
1 |
80% |
0.005 |
8158 |
4662 |
1.75 |
21 |
39,158,400 |
1c |
1 |
1 |
90% |
0.05 |
6439 |
3679 |
1.75 |
21 |
30,907,200 |
1d |
1 |
1 |
90% |
0.005 |
10244 |
5854 |
1.75 |
21 |
49,171,200 |
|
|
|
|
|
|
|
|
|
|
2a |
1 |
2 |
80% |
0.05 |
6764 |
3865 |
1.75 |
21 |
32,467,200 |
2b |
1 |
2 |
80% |
0.005 |
11472 |
6555 |
1.75 |
21 |
55,065,600 |
2c |
1 |
2 |
90% |
0.05 |
9054 |
5174 |
1.75 |
21 |
43,459,200 |
2d |
1 |
2 |
90% |
0.005 |
14405 |
8231 |
1.75 |
21 |
69,144,000 |
|
|
|
|
|
|
|
|
|
|
3a |
2 |
1 |
80% |
0.05 |
7730 |
4417 |
1.75 |
21 |
37,104,000 |
3b |
2 |
1 |
80% |
0.005 |
13111 |
7492 |
1.75 |
21 |
62,932,800 |
3c |
2 |
1 |
90% |
0.05 |
10348 |
5913 |
1.75 |
21 |
49,670,400 |
3d |
2 |
1 |
90% |
0.005 |
16463 |
9407 |
1.75 |
21 |
79,022,400 |
|
|
|
|
|
|
|
|
|
|
4a |
2 |
2 |
80% |
0.05 |
9620 |
5497 |
1.75 |
21 |
46,176,000 |
4b |
2 |
2 |
80% |
0.005 |
16316 |
9323 |
1.75 |
21 |
78,316,800 |
4c |
2 |
2 |
90% |
0.05 |
12878 |
7359 |
1.75 |
21 |
61,814,400 |
4d |
2 |
2 |
90% |
0.005 |
20488 |
11707 |
1.75 |
21 |
98,342,400 |
|
|
|
|
|
|
|
|
|
|
*Assuming 5.67% annual
HIV-1 incidence in the placebo and no treatment arms and 81% annual retention
rate. |
|
||||||||
**Assuming average
follow-up time of 21 months. |
|
|
|
|
|
Subcommittee
Convened Ad Hoc
To Prepare for FDA/CDER AVAC
Meeting,
Sandra Arnold
Vice President, Corporate Affairs
Population Council
Richard P. Bax, MD, FRCP, FFPM, MRCGP
Chief Scientific Officer
Biosyn, Inc.
Ward Cates, Jr. MD, MPH
President and CEO
Institute for Family Health
Family Health International
Anne Coletti
Senior Scientist
Family Health International
Rosalie Dominik, DrPH
Director of Biostatistics
Family Health International
Tim Farley, PhD
Coordinator, Department of Reproductive Health and
Research
World Health Organization
Henry Gabelnick, PhD
Director
Contraceptive Research and Development Program
Caroline Galbreath
Senior Manager, Regulatory Affairs
Biosyn, Inc.
Polly F. Harrison, PhD
Director
Sharon L. Hillier, PhD
Associate Professor
Magee-Women’s Hospital
Christine Mauck, MD, MPH
Senior Medical Advisor
Contraceptive Research and Development Program
Arlington, VA
Albert T. Profy, PhD
Vice President,
Preclinical Development
Interneuron
Pharmaceuticals, Inc.
Lexington, MA
Zeda Rosenberg, PhD
Chief Executive Officer
International Partnership for Microbicides
Jeffrey Spieler
Chief, Research, Technology and Utilization Division
USAID
Alan Stone DPhil, MD
Medical Scientific Advisory Services Ltd.
Don E. Waldron, PhD
Director, Clinical Research
Mark A. Weaver, PhD
Senior Biostatistician
Family Health Council
REFERENCES
[1] Annan KA. In
[2] Joint United Nations Programme on HIV/AIDS
(UNAIDS). Report on the global HIV/AIDS epidemic.
[3] Kaiser Family Foundation. Women and
HIV/AIDS fact sheet, July 2002; World Health Organization. Department of
HIV/AIDS/STI Report.
[4] Centers for Disease Control and Prevention.
Tracking the hidden epidemic: trends in STDs in the
[5] Fleming DT, Wasserheit J. From epidemiological synergy to public health policy and practice; the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sexually Transmitted Infections 75:3-17, 1999.
[6] Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Family Planning Perspectives 32;4:184-88, 2000.
[7] Hearst N, Chen S. Condoms for AIDS
prevention in the developing world: a review of the scientific literature.
[8]
[9] United Nations Development Programme. Human
development report.
[10] McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nature Medicine 9;7:874-880, July 2003.
[11] Gross M, Johnston MI. HIV vaccines and topical microbicides: a complementary combination. The Microbicide Quarterly 1;1, April-June 2003.
[12] Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nature Medicine 9;7:84752, July 2003; Shattock R. The rationale for combination microbicides: viral and cellular targets. The Microbicide Quarterly 1;2:1-5, July-September 2003.
[13] Feachem R. AIDS hasn’t peaked yet—and that’s
not the worst of it. Washington Post,
[14] This terminology originated in the 1993 CIOMS[14] International Ethical Guidelines for Biomedical Research Involving Human Subjects, which stated that the first Phase I trial of any pharmaceutical product should be conducted in the country where that product was developed and manufactured, referred to as the “country of origin.” The guideline was motivated by concerns about the exploitation of volunteers implicit in the testing in developing-country sites of drugs that would primarily benefit developed-country populations (termed “countries of use”). It was modified in the 2001
revision of the Guidelines, largely in deference to the realities of HIV/AIDS and the disparities between developed and developing countries with respect to burden of disease.
[15] Institute for International Research. Phases: maximizing clinical efficiency, 8-10 October 2003, Conference agenda. Available at http://www.iirusa.com/phases/index.cfm.
[16] Godwin J. HIV vaccines, microbicides, and treatments: developing an agenda for action—a discussion paper. Draft document, Canadian HIV/AIDS Legal Network, June 2003; Gross M, Johnston MI. HIV vaccines and topical microbicides: a complementary combination, Part 2—shared regulatory considerations. The Microbicide Quarterly 1;2:8-12, July-September 2003.
[17] The recommendation has been made that a
compendium be developed of “listed countries” that look to the FDA, as well as
to
[18]
[19] Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nature Medicine 9;7:867-73, July 2003.
[20] Joint United Nations Programme on HIV/AIDS
(UNAIDS). Report on the global HIV/AIDS epidemic.
[21] European Agency for the Evaluation of
Medicinal Products (EMEA). Ad hoc
meeting on regulatory pathways for vaccines for the developing world,
[22] Fauci, 2003, op. cit.
[23] Stone A. Clinical trials of microbicides. The Microbicide Quarterly 1;2:13-18, July-September 2003.
[24] Bhore R. Regulatory preferences, expectations, and requirements.
Presentation at Clinical Trials Mini-summit, 7th Meeting of the
[25] Roddy R. Welcome presentation: hurdles in microbicide clinical
trials. Presentation at Clinical Trials Mini-summit, 7th Meeting of
the